Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan A Randomized, Double-Blind, Multicenter Study

被引:16
|
作者
Hong, Bum-Kee [2 ]
Park, Chang Gyu [3 ]
Kim, Ki Sik [4 ]
Yoon, Myeong Ho [5 ]
Yoon, Ho Joong [6 ]
Yoon, Jeong Han [7 ]
Yang, Joo Young [8 ]
Choi, Young Jin [9 ]
Cho, Seung Yun [1 ]
机构
[1] Yonsei Univ, Coll Med, Cardiovasc Hosp, Div Cardiol, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Ctr Heart, Seoul, South Korea
[3] Korea Univ, Guro Hosp, Div Cardiol, Seoul, South Korea
[4] Daegu Catholic Univ, Med Ctr, Div Cardiol, Taegu, South Korea
[5] Ajou Univ, Med Ctr, Div Cardiol, Suwon, South Korea
[6] Catholic Univ, Seoul St Mary Hosp, Div Cardiol, Seoul, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Div Cardiol, Songnam, Gyeonggi Do, South Korea
[8] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Cardiol, Ilsan, South Korea
[9] Hallym Univ, Med Ctr, Hanging Sacred Heart Hosp, Div Cardiol, Seoul, South Korea
关键词
AMLODIPINE/VALSARTAN COMBINATION THERAPY; RECEPTOR ANTAGONIST; BLOOD-PRESSURE; PHARMACOKINETICS; TOLERABILITY; PREVENTION; VALSARTAN; OUTCOMES; TRIAL;
D O I
10.2165/11597410-000000000-00000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed-dose combination drugs may enhance blood pressure (BP) goal attainment through complementary effects and reduced side effects, which leads to better compliance. Objective: This study aimed to evaluate the efficacy and safety profiles of once-daily combination amlodipine/losartan versus losartan. Methods: This was an 8-week, double-blind, multicenter, randomized phase III study conducted in outpatient hospital clinics. Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg. The main outcome measures were changes in sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP) and BP response rate from baseline values, which were assessed after 4 and 8 weeks of treatment. Safety and tolerability were also assessed. Results: At week 8, both groups achieved significant reductions from baseline in DBP (11.7 +/- 7.0 and 3.2 +/- 7.9 mmHg), which was significantly greater in the amlodipine/losartan 5 mg/100 mg combination (n = 70) group (p < 0.0001). Additionally, the amlodipine/losartan 5 mg/100 mg combination group achieved significantly greater reductions in SBP at week 8 and in SBP and DBP at week 4 compared with the losartan 100 mg (n = 72) group (all p < 0.0001). Response rates were significantly higher in the amlodipine/losartan 5 mg/100 mg group versus the losartan 100 mg group (81.4% vs 63.9% at week 4, p < 0.0192; 90.0% vs 66.7% at week 8, p < 0.001). Both treatments were generally well tolerated. Conclusion: Switching to a fixed-dose combination therapy of amlodipine/losartan 5 mg/100 mg was associated with significantly greater reductions in BP and superior achievement of BP goals compared with a maintenance dose of losartan 100 mg in Korean patients with essential hypertension inadequately controlled on losartan 100 mg.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [21] Antihypertensive effect of a fixed-dose combination of losartan /hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study
    Tatsuo Hosoya
    Satoru Kuriyama
    Iwao Ohno
    Tetsuya Kawamura
    Makoto Ogura
    Masato Ikeda
    Masahiro Ishikawa
    Fumihiro Hayashi
    Tatsuya Kanai
    Haruo Tomonari
    Michimasa Soejima
    Kiyoaki Akaba
    Goro Tokudome
    Clinical and Experimental Nephrology, 2012, 16 : 269 - 278
  • [22] COMPARISON BETWEEN THE EFFECTS OF HYDROCHLOROTHIAZIDE AND INDAPAMIDE ON THE KIDNEY IN HYPERTENSIVE PATIENTS INADEQUATELY CONTROLLED WITH LOSARTAN
    Chen, Xiaoping
    Wang, Si
    Li, Jiangbo
    Zhou, Xiaoyan
    Liu, Kai
    Zhang, Xin
    Meng, Qingtao
    Shi, Rufeng
    Shi, Di
    JOURNAL OF HYPERTENSION, 2016, 34 : E389 - E389
  • [23] Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan
    S Wang
    J Li
    X Zhou
    K Liu
    X Zhang
    Q Meng
    R Shi
    D Shi
    X Chen
    Journal of Human Hypertension, 2017, 31 : 848 - 854
  • [24] Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases:: a double-blind, randomized clinical trial
    Praga, M
    Andrade, CF
    Luño, J
    Arias, M
    Poveda, R
    Mora, J
    Prat, MV
    Rivera, F
    Galceran, JM
    Ara, JM
    Aguirre, R
    Bernis, C
    Marín, R
    Campistol, JM
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (09) : 1806 - 1813
  • [25] Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan
    Wang, S.
    Li, J.
    Zhou, X.
    Liu, K.
    Zhang, X.
    Meng, Q.
    Shi, R.
    Shi, D.
    Chen, X.
    JOURNAL OF HUMAN HYPERTENSION, 2017, 31 (12) : 848 - 854
  • [26] PHARMACOKINETIC COMPARISON OF AMLODIPINE/LOSARTAN/ROSUVASTATIN FIXED-DOSE COMBINATION AND AMLODIPINE/LOSARTANFIXED-DOSE COMBINATION WITH ROUSUVASTATIN TABLET.
    Ban, M.
    Lee, S.
    Ryou, J. -H.
    Kim, E.
    Son, H.
    Jung, J.
    Yu, K. -S.
    Chung, J. -Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S24 - S25
  • [27] A RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-OR AMLODIPINE-CONTROLLED STUDY OF THE EFFECTS OF LOSARTAN ON PROTEINURIA IN CHILDREN WITH OR WITHOUT HYPERTENSION
    Webb, N. J. A.
    Lam, C.
    Loeys, T.
    Shahinfar, S.
    Strehlau, J.
    Wells, T. G.
    Santoro, E. Palumbo
    Manas, D.
    Gleim, G. W.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1785 - 1785
  • [28] Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial
    Lai, Xinxing
    Dong, Zhenyu
    Wu, Shengxian
    Zhou, Xiaohua
    Zhang, Genming
    Xiong, Shangquan
    Wu, Wei
    Cao, Rui
    Wang, Xiaolong
    Hua, Qi
    Du, Jinhang
    Fan, Jinying
    Mao, Jingyuan
    Jiang, Weimin
    Yuan, Huishu
    Chen, Yushan
    Xu, Yong
    Li, Zhanquan
    Zhang, Jun
    Dong, Guiying
    Zhen, Hui
    Ding, Ru
    Wu, Zonggui
    Gao, Ying
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (03): : E007923
  • [29] Efficacy and Safety of Mizoribine Combined With Losartan in the Treatment of IgA Nephropathy: A Multicenter, Randomized, Controlled Study
    Xie, Yuansheng
    Huang, Songmin
    Wang, Li
    Miao, Lining
    Zhang, Aiping
    Li, Ying
    Wu, Xiongfei
    Wang, Lining
    Liu, Shuxin
    Lie, Caihua
    Chen, Pu
    Chen, Xiangmei
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (05): : 367 - 372
  • [30] BENEFICIAL EFFECT OF ADDING LOSARTAN TO FIXED-DOSE OF LOSARTAN 50 MG / HYDROCHLOROTHIAZIDE 12.5 MG ON ALBUMINURIA AND URIC ACID METABOLISM IN HYPERTENSIVE PATIENTS
    Sunagawa, Yoshitsugu
    Kohagura, Kentaro
    Yamazato, Masanobu
    Ishida, Akio
    Sakima, Atsushi
    Ohya, Yusuke
    JOURNAL OF HYPERTENSION, 2018, 36 : E224 - E224